JP2016525545A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525545A5
JP2016525545A5 JP2016529759A JP2016529759A JP2016525545A5 JP 2016525545 A5 JP2016525545 A5 JP 2016525545A5 JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016525545 A5 JP2016525545 A5 JP 2016525545A5
Authority
JP
Japan
Prior art keywords
fusion antibody
acid sequence
amino acid
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016529759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525545A (ja
JP6692293B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/038660 external-priority patent/WO2015012944A1/en
Publication of JP2016525545A publication Critical patent/JP2016525545A/ja
Publication of JP2016525545A5 publication Critical patent/JP2016525545A5/ja
Priority to JP2020072208A priority Critical patent/JP6914392B2/ja
Application granted granted Critical
Publication of JP6692293B2 publication Critical patent/JP6692293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016529759A 2013-07-22 2014-05-19 Cnsにおける酵素活性を増大するための方法および組成物 Active JP6692293B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020072208A JP6914392B2 (ja) 2013-07-22 2020-04-14 Cnsにおける酵素活性を増大するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361857140P 2013-07-22 2013-07-22
US61/857,140 2013-07-22
PCT/US2014/038660 WO2015012944A1 (en) 2013-07-22 2014-05-19 Methods and compositions for increasing enzyme activity in the cns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020072208A Division JP6914392B2 (ja) 2013-07-22 2020-04-14 Cnsにおける酵素活性を増大するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2016525545A JP2016525545A (ja) 2016-08-25
JP2016525545A5 true JP2016525545A5 (enExample) 2017-06-29
JP6692293B2 JP6692293B2 (ja) 2020-05-13

Family

ID=51023055

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016529759A Active JP6692293B2 (ja) 2013-07-22 2014-05-19 Cnsにおける酵素活性を増大するための方法および組成物
JP2020072208A Active JP6914392B2 (ja) 2013-07-22 2020-04-14 Cnsにおける酵素活性を増大するための方法および組成物
JP2021115534A Pending JP2021180658A (ja) 2013-07-22 2021-07-13 Cnsにおける酵素活性を増大するための方法および組成物
JP2023153971A Pending JP2024012225A (ja) 2013-07-22 2023-09-20 Cnsにおける酵素活性を増大するための方法および組成物
JP2024230169A Pending JP2025041923A (ja) 2013-07-22 2024-12-26 Cnsにおける酵素活性を増大するための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020072208A Active JP6914392B2 (ja) 2013-07-22 2020-04-14 Cnsにおける酵素活性を増大するための方法および組成物
JP2021115534A Pending JP2021180658A (ja) 2013-07-22 2021-07-13 Cnsにおける酵素活性を増大するための方法および組成物
JP2023153971A Pending JP2024012225A (ja) 2013-07-22 2023-09-20 Cnsにおける酵素活性を増大するための方法および組成物
JP2024230169A Pending JP2025041923A (ja) 2013-07-22 2024-12-26 Cnsにおける酵素活性を増大するための方法および組成物

Country Status (6)

Country Link
US (3) US20150023956A1 (enExample)
EP (2) EP3024848B1 (enExample)
JP (5) JP6692293B2 (enExample)
AU (2) AU2014293626A1 (enExample)
CA (1) CA2918579C (enExample)
WO (1) WO2015012944A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
WO2011044542A1 (en) 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
JP6266529B2 (ja) * 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドArmagen, Inc. Cnsにおけるアリールスルファターゼa活性を増加するための方法および組成物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
AU2019317460A1 (en) * 2018-08-07 2021-03-18 Armagen, Inc. Methods and compositions for increasing the activity in the CNS of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1
WO2022081765A1 (en) 2020-10-14 2022-04-21 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2023214833A1 (ko) * 2022-05-04 2023-11-09 이뮤노포지 주식회사 Glp-1, 면역글로불린 fc, 및 igf-1을 포함하는 융합단백질 및 이의 용도
WO2023240220A1 (en) * 2022-06-09 2023-12-14 The University Of North Carolina At Chapel Hill Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
TW279133B (enExample) 1990-12-13 1996-06-21 Elan Med Tech
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US6195608B1 (en) 1993-05-28 2001-02-27 Lucent Technologies Inc. Acoustic highway monitor
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
PT851753E (pt) 1995-09-19 2004-04-30 Fujisawa Pharmaceutical Co Composicoes em aerossol
WO1998054213A2 (en) * 1997-05-30 1998-12-03 Amgen Inc. Neurotrophic factor receptors
US6016800A (en) 1997-10-24 2000-01-25 Century; Theodore J. Intrapulmonary aerosolizer
EP1037687B8 (en) 1997-12-11 2008-10-22 Alza Corporation Device for enhancing transdermal agent flux
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
CN1759176B (zh) * 2003-02-11 2012-10-03 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
MX2013000320A (es) * 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
LT2646470T (lt) * 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
CA2822559C (en) * 2010-12-22 2021-11-30 Fondazione Telethon Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
JP6266529B2 (ja) * 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドArmagen, Inc. Cnsにおけるアリールスルファターゼa活性を増加するための方法および組成物
EP2854834A4 (en) * 2012-05-30 2016-05-18 Biostrategies LC PLANT LENSES AS CARRIER CORRESPONDING AGENTS IN ANIMAL AND HUMAN CELLS

Similar Documents

Publication Publication Date Title
JP2016525545A5 (enExample)
CN107921122B (zh) 与cd38结合的抗体治疗剂
JP7663977B2 (ja) 抗pd―l1抗体およびその用途
JP2013507131A5 (enExample)
JP2014511680A5 (enExample)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
RU2018113505A (ru) Il-8-связывающие антитела и их применения
JP2010502207A5 (enExample)
JP2020500538A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2015530983A5 (enExample)
JP2016502515A5 (enExample)
JP2019502656A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2017529097A5 (enExample)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
JP2011509245A5 (enExample)
JP2015522252A5 (enExample)
JP2017536102A5 (enExample)
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2017529870A5 (enExample)
JP2013531993A5 (enExample)
WO2017060322A3 (en) Ptefb-inhibitor-adc
JP2014530001A5 (enExample)
JP2018512124A5 (enExample)
RU2014109093A (ru) Антитела против нейрегулина и их применение